查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1455079

全球囊肿纤维化治疗市场规模、份额、成长分析（按药物类别、给药途径）-产业预测，2024-2031 年

Global Cystic Fibrosis Therapeutics Market Size, Share, Growth Analysis, By Drug Class(CFTR modulators, Mucolytics), By Route of Administration(Oral drugs and Inhaled drugs) - Industry Forecast 2024-2031
出版日期: | 出版商: SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格
简介目录

囊肿纤维化治疗的全球市场规模预计到2022 年约为53 亿美元，高于2023 年的60.2 亿美元，预测期内（2023-2031 年）复合年增长率为13.50%，到2031 年预计将达到2019年为165.7亿美元。

囊肿纤维化（CF）盛行率的上升和治疗率的提高是整个预测期内推动囊肿纤维化治疗需求的关键原因。此外，非营利组织开展的计划数量不断增加、公共和私人来源的研发资金不断增加、有利的报销政策等是预计未来几年塑造市场的关键因素。这只是其中的一小部分。它。

随着患者数量逐年增加，对有效且经济的CF治疗的需求不断增长。常用的药物类别包括支气管扩张剂、黏液溶解剂、抗感染剂、抗生素（口服、吸入和肠胃外）、发炎药物和胰酵素补充品。囊肿纤维化跨膜电导调节剂 (CFTR) 调节剂也包含在此清单中。

主要企业正在开发的药物组合物数量不断增加是预计推动市场扩张的关键因素之一。此外，市场的驱动因素之一是越来越多的研究正在进行，以扩大使用当前治疗组合的目标客户。市场扩张预计将由研发活动的活性化所推动。

另一个可能推动囊肿纤维化治疗市场成长的关键因素是越来越多的公司参与 CF 相关活动，例如 CF Worldwide、Cystic Fibrosis Organization、Cystic Fibrosis Canada、South Africa Cystic Fibrosis Confidence 和 South African囊性纤维化组织。我们定期参加许多慈善机构。这些组织支持重大研究和开发工作，并花费大量资金来发现囊肿纤维化的新治疗方法。

目录

执行摘要

  • 市场概况
  • 繁荣与衰落

调查方法

  • 资讯采购
  • 次要和主要资料来源
  • 市场规模估算
  • 市场假设与限制

母市场分析

  • 市场概况
  • 市场规模
  • 市场动态
    • 促进因素
    • 机会
    • 抑制因素
    • 任务

主要市场考察

  • 技术分析
  • 价格分析
  • 供应链分析
  • 价值链分析
  • 市场生态系统
  • 智慧财产权分析
  • 贸易分析
  • Start-Ups分析
  • 原料分析
  • 创新矩阵
  • 研发线产品分析
  • 总体经济指标
  • 主要投资分析
  • 关键成功因素
  • 竞争程度

市场动态及前景

  • 市场动态
    • 促进因素
    • 机会
    • 抑制因素
    • 任务
  • 监管环境
  • 波特的分析
  • 对未来中断的特殊考虑

全球囊肿纤维化治疗市场：依药物类别

  • 市场概况
  • CF处理剂
  • 黏液溶解剂
  • 胰补充品
  • 支气管扩张剂

全球囊肿纤维化治疗市场：依给药途径

  • 市场概况
  • 口服和吸入药物

全球囊肿纤维化治疗市场规模（按地区）

  • 市场概况
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 西班牙
    • 法国
    • 英国
    • 其他欧洲地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 其他亚太地区
  • 拉丁美洲
    • 巴西
    • 其他拉丁美洲地区
  • 中东/非洲
    • 海湾合作委员会国家
    • 南非
    • 其他中东/非洲地区

竞争格局

  • 前5名企业对比
  • 主要企业市场定位（2021年）
  • 主要市场参与者所采取的策略
  • 关键成功策略
  • 近期市集活动
  • 主要企业市场占有率（2021年）

主要企业简介

  • Vertex Pharmaceuticals Incorporated
  • AbbVie Inc.
  • Gilead Sciences, Inc.
  • Genentech, Inc.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Mylan NV
  • Perrigo Company plc
  • Pharmaxis Ltd.
  • Celtaxsys, Inc.
  • Savara Inc.
  • Kamada Ltd.
  • Chiesi Farmaceutici SpA
  • Galapagos NV
  • Proteostasis Therapeutics, Inc.
  • Eloxx Pharmaceuticals, Inc.
  • Insmed Incorporated
  • Arcturus Therapeutics Holdings Inc.
  • Translate Bio, Inc.
  • Zogenix, Inc.
简介目录
Product Code: SQMIG35I2224

Global Cystic Fibrosis Therapeutics Market size was valued at around 5.30 billion in 2022 and is expected to rise from USD 6.02 billion in 2023 to reach a value of USD 16.57 Billion by 2031, at a CAGR of 13.50% over the forecast period (2023-2031).

The rising prevalence of cystic fibrosis (CF) along with an increasing treatment rate is one of the major reasons driving demand for cystic fibrosis treatments throughout the forecast period. In addition, more projects carried out by nonprofit organizations, more funding for research and development from both public and private sources, and the availability of advantageous reimbursement policies are just a few of the crucial factors anticipated to shape the market in the years to come.

The demand for effective and economical CF medicines rises as a result of an increase in patient growth year over year. A few easily accessible approved drug classes include bronchodilators, mucolytic medications, anti-infective, antibiotics (oral, inhaled, or parents feeding formulae), anti-inflammatory, and pancreatic enzyme supplements. Cystic fibrosis Transmembrane Conductivity Regulator (CFTR) modulators are also included in this list.

The rising number of drug compositions that the top players have in the works is one of the key factors anticipated to fuel market expansion. Moreover, one of the market's drivers is the increasing number of studies being carried out to broaden its target clientele using its current treatment portfolio. Market expansion is expected to be driven by increasing R&D activity.

Another significant factor that may be driving the growth of the cystic fibrosis therapeutics market is the existence of numerous charitable organizations that are regularly involved in CF-related activities, such as CF Worldwide, Cystic Fibrosis Organization, Cystic Fibrosis Canada, South African Cystic Fibrosis Confidence, and South African Cystic Fibrosis Organization. These groups are spending a lot of money to support the research and development efforts of major players and to discover new treatments for cystic fibrosis.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cystic Fibrosis Therapeutics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cystic Fibrosis Therapeutics Market Segmental Analysis

The drug class, administration method, and geographic regions are the main factors that divide the worldwide market for cystic fibrosis therapies. The pancreatic enzyme supplements, CFTR modulators, mucolytics, and bronchodilators are the medication classes into which the market is divided. The market is divided into two categories based on the mode of administration: oral medications and inhaled drugs. The global market for cystic fibrosis treatments is divided into five regions: North America, Europe, Asia-Pacific, South America, and MEA.

Drivers of the Global Cystic Fibrosis Therapeutics Market

The market for cystic fibrosis treatments is primarily driven by the rising incidence of cystic fibrosis, a genetic condition affecting the reproductive, digestive, and respiratory systems. The need for cystic fibrosis therapies is fueled by the disease's irreversibility and lifetime treatment requirements.

Restraints in the Global Cystic Fibrosis Therapeutics Market

A significant obstacle to therapy availability for many people with cystic fibrosis is the high expense of available medicines, especially the more targeted ones. This has raised questions over these medications' cost and potential effects on healthcare systems.

Market Trends of the Global Cystic Fibrosis Therapeutics Market

Growing need for individualized therapy: As our knowledge of the genetic underpinnings of cystic fibrosis expands, so does the need for personalized medicine that specifically addresses the mutations that cause the illness. As more advanced treatments that target certain mutations are created, it is anticipated that this trend will continue in the years to come.

Use of combination medicines is rising: Combination medications, which address several mutations at once, are being used more frequently to treat cystic fibrosis. This is because treating many variants can improve outcomes, and many patients have multiple mutations contributing to their condition.

Growth in interest in creating treatments for non-classic mutations has been observed despite the majority of research in cystic fibrosis medications being concentrated on the most prevalent variants. Although certain mutations are less frequent, they can nevertheless contribute to the illness, and many people may benefit from treatments that specifically target them.

Growing emphasis on disease management: Despite the fact that there is currently no treatment for cystic fibrosis, patients' quality of life is being improved and disease management is receiving more attention. This involves creating treatments that specifically address the disease's symptoms as well as using nutritional and respiratory therapy to enhance general health and lung function.

Growing significance of patient advocacy: When it comes to the creation and acceptance of new cystic fibrosis treatments, patients and patient advocacy organizations are becoming more and more involved. This is partly because a lot of these therapies are pricey and might not be covered by insurance, which makes it hard for patients to get them on their own without assistance from organizations and advocacy groups.

Table of Contents

Executive Summary

  • Market Overview
  • Wheel of Fortune

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations

Parent Market Analysis

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges

Key Market Insights

  • Technology Analysis
  • Pricing Analysis
  • Supply Chain Analysis
  • Value Chain Analysis
  • Ecosystem of the Market
  • IP Analysis
  • Trade Analysis
  • Startup Analysis
  • Raw Material Analysis
  • Innovation Matrix
  • Pipeline Product Analysis
  • Macroeconomic Indicators
  • Top Investment Analysis
  • Key Success Factor
  • Degree of Competition

Market Dynamics & Outlook

  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges
  • Regulatory Landscape
  • Porters Analysis
    • Competitive rivalry
    • Threat of Substitute Products
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers
  • Skyquest Special Insights on Future Disruptions
    • Political Impact
    • Economic Impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Global Cystic Fibrosis Therapeutics Market by Drug Class

  • Market Overview
  • CFTR modulators
  • Mucolytics
  • Pancreatic enzyme supplements
  • and Bronchodilators

Global Cystic Fibrosis Therapeutics Market by Route of Administration

  • Market Overview
  • Oral drugs and Inhaled drugs

Global Cystic Fibrosis Therapeutics Market Size by Region

  • Market Overview
  • North America
    • USA
    • Canada
  • Europe
    • Germany
    • Spain
    • France
    • UK
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC Countries
    • South Africa
    • Rest of MEA

Competitive Landscape

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2021
  • Strategies Adopted by Key Market Players
  • Top Winning Strategies
    • By Development
    • By Company
    • By Year
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2021

Key Company Profiles

  • Vertex Pharmaceuticals Incorporated
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AbbVie Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Gilead Sciences, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Genentech, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novartis AG
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Teva Pharmaceutical Industries Ltd.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Mylan N.V.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Perrigo Company plc
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pharmaxis Ltd.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Celtaxsys, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Savara Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Kamada Ltd.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Chiesi Farmaceutici S.p.A.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Galapagos NV
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Proteostasis Therapeutics, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Eloxx Pharmaceuticals, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Insmed Incorporated
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Arcturus Therapeutics Holdings Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Translate Bio, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Zogenix, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments